BioIntelliSense has received 510(k) approval from the US Food and Drug Administration (FDA) for its BioSticker on-body sensor for scalable remote care.

BioSticker is an on-body sensor that enables constant monitoring of critical signs and actionable insights of patients.

The platform assists doctors to access data from patients in the home setting, leading to early detection of potentially avoidable complications.

BioIntelliSense has also commercially launched its medical-grade Data-as-a-Service (DaaS) platform in the US.

DaaS platform captures vital signs every minute, as well as physiological biometrics and symptomatic events, providing an effortless experience for patients.

With the help of the platform’s advanced analytics, doctors can generate high-resolution patient trending and reporting to provide medical-grade care at homes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioIntelliSense CEO Dr James Mault said: “We are at the inception of a remarkable new era in healthcare that will employ medical-grade sensor technologies to effortlessly capture remote patient data and generate personalised clinical intelligence.”

BioIntelliSense has entered into a strategic partnership with UCHealth and its CARE Innovation Center to show the clinical applications of the BioSticker device and medical-grade services.

The partnership aims to build and validate models of data-driven care, patient-centred and designed for scale.

UCHealth chief innovation officer Dr Richard Zane said: “The use of the BioSticker device for continuous health monitoring enables us to monitor a patient in their home and recognize when a patient may have an exacerbation of illness even before they manifest symptoms.

“This may reduce hospitalisations, emergency department visits and shorten hospital stays, creating cost efficiencies for health systems.”

Last July, Fresenius Medical Care North America invested in BioIntelliSense, which is working on a medical-grade data services platform for continuous, remote patient monitoring.